Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase...
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study
About this item
Full title
Author / Creator
Publisher
Kidlington: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background Eltrombopag is an oral thrombopoietin receptor agonist for the treatment of thrombocytopenia. We aimed to compare the response to once daily eltrombopag versus placebo in patients with chronic immune thrombocytopenia during a 6-month period. Methods We undertook a phase 3, double-blind, placebo-controlled study in adults with pre...
Alternative Titles
Full title
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_856790655
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_856790655
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(10)60959-2
